Literature DB >> 26718501

Variation in SLC19A3 and Protection From Microvascular Damage in Type 1 Diabetes.

Massimo Porta1, Iiro Toppila2, Niina Sandholm2, S Mohsen Hosseini3, Carol Forsblom2, Kustaa Hietala4, Lorenzo Borio1, Valma Harjutsalo5, Barbara E Klein6, Ronald Klein6, Andrew D Paterson3, Per-Henrik Groop7.   

Abstract

The risk of long-term diabetes complications is not fully explained by diabetes duration or long-term glycemic exposure, suggesting the involvement of genetic factors. Because thiamine regulates intracellular glucose metabolism and corrects for multiple damaging effects of high glucose, we hypothesized that variants in specific thiamine transporters are associated with risk of severe retinopathy and/or severe nephropathy because they modify an individual's ability to achieve sufficiently high intracellular thiamine levels. We tested 134 single nucleotide polymorphisms (SNPs) in two thiamine transporters (SLC19A2/3) and their transcription factors (SP1/2) for an association with severe retinopathy or nephropathy or their combination in the FinnDiane cohort. Subsequently, the results were examined for replication in the DCCT/EDIC and Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) cohorts. We found two SNPs in strong linkage disequilibrium in the SLC19A3 locus associated with a reduced rate of severe retinopathy and the combined phenotype of severe retinopathy and end-stage renal disease. The association for the combined phenotype reached genome-wide significance in a meta-analysis that included the WESDR cohort. These findings suggest that genetic variations in SLC19A3 play an important role in the pathogenesis of severe diabetic retinopathy and nephropathy and may explain why some individuals with type 1 diabetes are less prone than others to develop microvascular complications.
© 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26718501      PMCID: PMC4806664          DOI: 10.2337/db15-1247

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  40 in total

1.  The pathobiology of diabetic complications: a unifying mechanism.

Authors:  Michael Brownlee
Journal:  Diabetes       Date:  2005-06       Impact factor: 9.461

2.  Principal components analysis corrects for stratification in genome-wide association studies.

Authors:  Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich
Journal:  Nat Genet       Date:  2006-07-23       Impact factor: 38.330

3.  PLINK: a tool set for whole-genome association and population-based linkage analyses.

Authors:  Shaun Purcell; Benjamin Neale; Kathe Todd-Brown; Lori Thomas; Manuel A R Ferreira; David Bender; Julian Maller; Pamela Sklar; Paul I W de Bakker; Mark J Daly; Pak C Sham
Journal:  Am J Hum Genet       Date:  2007-07-25       Impact factor: 11.025

Review 4.  Validating, augmenting and refining genome-wide association signals.

Authors:  John P A Ioannidis; Gilles Thomas; Mark J Daly
Journal:  Nat Rev Genet       Date:  2009-05       Impact factor: 53.242

5.  Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study).

Authors:  Lena M Thorn; Carol Forsblom; Johan Fagerudd; Merlin C Thomas; Kim Pettersson-Fernholm; Markku Saraheimo; Johan Wadén; Mats Rönnback; Milla Rosengård-Bärlund; Clas-Göran Af Björkesten; Marja-Riitta Taskinen; Per-Henrik Groop
Journal:  Diabetes Care       Date:  2005-08       Impact factor: 19.112

6.  Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy.

Authors:  Holger Schmid; Anissa Boucherot; Yoshinari Yasuda; Anna Henger; Bodo Brunner; Felix Eichinger; Almut Nitsche; Eva Kiss; Markus Bleich; Hermann-Josef Gröne; Peter J Nelson; Detlef Schlöndorff; Clemens D Cohen; Matthias Kretzler
Journal:  Diabetes       Date:  2006-11       Impact factor: 9.461

7.  Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose.

Authors:  Elena Berrone; Elena Beltramo; Carmela Solimine; Alessandro Ubertalli Ape; Massimo Porta
Journal:  J Biol Chem       Date:  2006-02-01       Impact factor: 5.157

8.  Oral benfotiamine plus alpha-lipoic acid normalises complication-causing pathways in type 1 diabetes.

Authors:  X Du; D Edelstein; M Brownlee
Journal:  Diabetologia       Date:  2008-07-29       Impact factor: 10.122

9.  High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease.

Authors:  P J Thornalley; R Babaei-Jadidi; H Al Ali; N Rabbani; A Antonysunil; J Larkin; A Ahmed; G Rayman; C W Bodmer
Journal:  Diabetologia       Date:  2007-08-04       Impact factor: 10.122

10.  Heritability of proliferative diabetic retinopathy.

Authors:  Kustaa Hietala; Carol Forsblom; Paula Summanen; Per-Henrik Groop
Journal:  Diabetes       Date:  2008-04-28       Impact factor: 9.461

View more
  12 in total

Review 1.  Progress in Defining the Genetic Basis of Diabetic Complications.

Authors:  Emma Dahlström; Niina Sandholm
Journal:  Curr Diab Rep       Date:  2017-09       Impact factor: 4.810

2.  Genetics: Risk of microvascular complications of T1DM.

Authors:  Claire Greenhill
Journal:  Nat Rev Endocrinol       Date:  2016-01-22       Impact factor: 43.330

3.  Blood thiamine pyrophosphate concentration and its correlation with the stage of diabetic retinopathy.

Authors:  Emine Cinici; Nilay Dilekmen; Onur Senol; Eren Arpalı; Ozkan Cinici; Serdar Tanas
Journal:  Int Ophthalmol       Date:  2020-07-26       Impact factor: 2.031

Review 4.  Unraveling the role of genetics in the pathogenesis of diabetic retinopathy.

Authors:  Ashok Sharma; Maria L Valle; Connor Beveridge; Yutao Liu; Shruti Sharma
Journal:  Eye (Lond)       Date:  2019-01-24       Impact factor: 3.775

5.  Effects of thiamine and fenofibrate on high glucose and hypoxia-induced damage in cell models of the inner blood-retinal barrier.

Authors:  Aurora Mazzeo; Chiara Gai; Marina Trento; Massimo Porta; Elena Beltramo
Journal:  Acta Diabetol       Date:  2020-07-12       Impact factor: 4.280

6.  Genome-wide association studies identify two novel loci conferring susceptibility to diabetic retinopathy in Japanese patients with type 2 diabetes.

Authors:  Minako Imamura; Atsushi Takahashi; Masatoshi Matsunami; Momoko Horikoshi; Minoru Iwata; Shin-Ichi Araki; Masao Toyoda; Gayatri Susarla; Jeeyun Ahn; Kyu Hyung Park; Jinhwa Kong; Sanghoon Moon; Lucia Sobrin; Toshimasa Yamauchi; Kazuyuki Tobe; Hiroshi Maegawa; Takashi Kadowaki; Shiro Maeda
Journal:  Hum Mol Genet       Date:  2021-05-17       Impact factor: 5.121

7.  The Usefulness of Serum Biomarkers in the Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial.

Authors:  Cristina Hernández; Massimo Porta; Francesco Bandello; Jakob Grauslund; Simon P Harding; Stephen J Aldington; Catherine Egan; Ulrik Frydkjaer-Olsen; José García-Arumí; Jonathan Gibson; Gabriele E Lang; Rosangela Lattanzio; Pascale Massin; Edoardo Midena; Berta Ponsati; Luísa Ribeiro; Peter Scanlon; José Cunha-Vaz; Rafael Simó
Journal:  J Clin Med       Date:  2020-04-24       Impact factor: 4.241

8.  Thiamine transporter 2 is involved in high glucose-induced damage and altered thiamine availability in cell models of diabetic retinopathy.

Authors:  Elena Beltramo; Aurora Mazzeo; Tatiana Lopatina; Marina Trento; Massimo Porta
Journal:  Diab Vasc Dis Res       Date:  2019-11-14       Impact factor: 3.291

9.  Investigation of candidate genes and mechanisms underlying obesity associated type 2 diabetes mellitus using bioinformatics analysis and screening of small drug molecules.

Authors:  G Prashanth; Basavaraj Vastrad; Anandkumar Tengli; Chanabasayya Vastrad; Iranna Kotturshetti
Journal:  BMC Endocr Disord       Date:  2021-04-26       Impact factor: 2.763

10.  Thiamine and diabetes: back to the future?

Authors:  Elena Beltramo; Aurora Mazzeo; Massimo Porta
Journal:  Acta Diabetol       Date:  2021-06-05       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.